HRD detection predicts sensitivity to platinum-based chemotherapy for ovarian cancer patients in China
Homologous Recombination Deficiency (HRD) is a biomarker that predicts ovarian cancer treatment with PARP inhibitors or breast cancer treatment with first-line platinum-based chemotherapy. However, limited research is documented ...
Apr 25, 2023
0
5